Carl L. Gordon, Director, 10% Owner at Kinnate Biopharma Inc. (KNTE), bought 2,754,946 shares at $2.75 ($7.7M) on 2023-05-04, disclosed to the SEC on 2023-05-08.
Open-market purchase of $7.7M KNTE by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.75 | 83,459 | $230K | 3.0% |
| 2 | $2.75 | 83,459 | $230K | 3.0% |
| 3 | $2.75 | 312,991 | $861K | 11.2% |
| 4 | $2.75 | 312,991 | $861K | 11.2% |
| 5 | $2.82 | 490,511 | $1.4M | 17.9% |
| 6 | $2.82 | 490,511 |
| $1.4M |
| 17.9% |
| 7 | $2.82 | 490,512 | $1.4M | 17.9% |
| 8 | $2.82 | 490,512 | $1.4M | 17.9% |
| Total | $2.80 avg | 2,754,946 | $7.7M | 100% |
| Filing → |
| SCTX | BUY | 2026-07-29 | $15.0M | — | Filing → |
| CMPX | SELL | 2025-04-11 | $11.4M | — | Filing → |
| MBX | BUY | 2025-02-19 | $2.7M | — | Filing → |